aXichem AB

Stockholm Stock Exchange AXIC-A.ST

aXichem AB Operating Income for the year ending December 31, 2023: USD -1.71 M

aXichem AB Operating Income is USD -1.71 M for the year ending December 31, 2023, a -23.05% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

aXichem AB Operating Income for the year ending December 31, 2022 was USD -1.39 M, a 16.28% change year over year.
aXichem AB Operating Income for the year ending December 31, 2021 was USD -1.66 M, a -1.31% change year over year.
aXichem AB Operating Income for the year ending December 31, 2020 was USD -1.64 M, a -23.70% change year over year.
aXichem AB Operating Income for the year ending December 31, 2019 was USD -1.32 M, a -21.76% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Stockholm Stock Exchange: AXIC-A.ST

aXichem AB

CEO	Mr. Torsten Helsing
IPO Date	March 4, 2011
Location	Sweden
Headquarters	Södergatan 26
Employees	7
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, an natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen-feed, a solution for enhanced health for chickens, hens, pigs, and piglets. The company was incorporated in 2007 and is based in Malmö, Sweden.

Key trends

Past 5 years